Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amgen CEO Gets 4 Percent Boost in Compensation

By Pharmaceutical Processing | March 10, 2009

NEW YORK (AP) — Amgen Inc. Chairman and Chief Executive Kevin Sharer’s compensation rose 4 percent to just under $13.8 million in 2008 as the company’s stock recovered from safety issues over its anemia drugs while Wall Street focused on a potential blockbuster osteoporosis treatment. Sharer earned $1,561,923 in salary and $3,875,000 in performance bonuses during the year, both marking boosts from 2007, according to a proxy statement filed with the Securities and Exchange Commission. Meanwhile, other compensation fell 41 percent to $530,697 as the company cut costs. The compensation consisted mostly of $181,275 for use of the company jet and $285,000 in retirement compensation. The bulk of his compensation, which is stock options, fell 16 percent to $7,812,869. The Associated Press’ compensation formula is designed to isolate the value the company’s board placed on the executive’s total compensation package during the last fiscal year. It includes salary, bonus, performance-related bonuses, perks, above-market returns on deferred compensation and the estimated value of stock options and awards granted during the year. The calculations don’t include changes in the present value of pension benefits, and they sometimes differ from the totals companies list in the summary compensation table of proxy statements filed with the Securities and Exchange Commission, which reflect the size of the accounting charge taken for the executive’s compensation in the previous fiscal year. Thousand Oaks, Calif.-based Amgen saw its stock price rise about 24 percent in 2008 as it rolled out a steady beat of positive clinical trial data on denosumab, which is now under Food and Drug Administration review. The drug is aimed at treating osteoporosis and Wall Street is considering it the company’s next blockbuster opportunity. The positive announcements follow a year of concerns over the company’s anemia drugs Aranesp and Epogen. Sales of the products have fallen in the wake of stricter safety warnings. Also in 2008, the company’s profit jumped 32 percent to $4.2 billion on a 20 percent boost in revenue, to $15 billion.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE